SAB Biotherapeutics (SABSW) to Release Quarterly Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABSW) is expected to post its resultson Thursday, March 26th. Analysts expect SAB Biotherapeutics to post earnings of ($0.2138) per share for the quarter.

SAB Biotherapeutics Stock Down 1.7%

Shares of SABSW opened at $0.03 on Thursday. The business’s 50 day moving average is $0.03 and its two-hundred day moving average is $0.03. SAB Biotherapeutics has a 52-week low of $0.02 and a 52-week high of $0.18.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.

The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.